Genetically Informed Smoking Cessation Trial

Phase 4 Completed 822 enrolled Washington University School of Medicine National Institute on Drug Abuse (NIDA) · collab National Institutes of Health (NIH) · collab

RandomizedParallel-groupTriple-blindPrevention

Summary

The investigators' goal is to identify the most appropriate smoking cessation treatments for smokers based on genetic information. Smokers try to quit smoking but relapses are common.

Timeline

Start: 2015-05-20
Primary completion: 2018-12-26
Completion: 2019-08-31

Publications

Chen LS, Baker TB, Miller JP, Bray M, Smock N, Chen J, Stoneking F, Culverhouse RC, Saccone NL, Amos CI, Carney RM, Jorenby DE, Bierut LJ. Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial. Clin Pharmacol Ther. 2020 Dec;108(6):1315-1325. doi: 10.1002/cpt.1971. Epub 2020 Aug 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Nicotine	Unknown	—	Other
Comparator	Varenicline	Small molecule	—	Oral

Indications

No indication recorded.